Biotech Series B Investors & VC Firms
725 firms in this list, with a median first check of $500K. 165 of them lead rounds. Generated from verified public data and updated continuously.
Teewinot Ventures
Pre-Seed–Late Stage
Zhangjiang Hi-Tech incubation ecosystem
ShanghaiPre-Seed–Growth
Oceanpine Capital
BeijingSeries A–Late Stage
5 people
Zhejiang Sino Wisdom Investment Co.,Ltd.
HangzhouSeries A–Late Stage
5 people
Vincera Capital
TaipeiSeed–Late Stage$500K – $10M
2 people
Otherwise
Mill ValleyPre-Seed–Series B
2 people
HALLEY Venture Partners
San FranciscoSeed–Series C
3 people
Oriza Holdings
SuzhouSeed–Series C
2 people
Japan Asia Investment
TokyoPre-Seed–Late Stage$1M – $10M
1 person
Alliance Jura-Hongrie Venture Capital Fund Management
BudapestSeries A–Series B$324K – $2.8M
1 person
Alpha Ventures
AthensSeries A–Series B$1.6M – $10.8M
1 person
Kenson Ventures, LLC
Menlo ParkSeed–Late Stage$500K – $3M
1 person
Company K Partners
SeoulSeries A–Series B
Augere Venture
KrakówSeed–Late Stage
2 people
SL Investment Ltd.
SeoulSeries A–Late Stage$500K – $2M
West Virginia Jobs Investment Trust
CharlestonSeed–Late Stage$100K – $1M
Wild Basin Investments
TexasSeed–Growth
2 people
Brandon Capital Partners
MelbourneSeed–Growth
1 person
Nan Fung Life Sciences
Hong KongSeed–Growth
1 person
Chang'an Capital
BeijingSeed–Series B
3 people
Harriet Ventures
Series A–Growth$500K – $50M
CBC Group
SingaporeSeed–Late Stage
2 people
Pittsburgh Life Sciences Greenhouse
PittsburghSeed–Series B
1 person
Entrepreneurs Fund
LondonSeries A–Growth
2 people
Related lists
Series B Investors & VC Firms (2956)Biotech Investors & VC Firms (2489)Biotech Seed Investors & VC Firms (2031)Series B Investors & VC Firms in North America (1738)Biotech Series A Investors & VC Firms (1629)Biotech Investors & VC Firms in North America (1606)Series B Investors & VC Firms in United States (1573)Biotech Investors & VC Firms in United States (1455)SaaS Series B Investors & VC Firms (1077)Series B Investors & VC Firms in Europe (1073)
Data sourced from public filings and firms' own websites — see our methodology.









